Sanam Shahid, MD

Professional Titles

• Assistant Professor

Publications

• Ceglia N, Salehi S, Sethna ZM, Elhanati Y, Freeman SS, Lyudovyk O, Burman B, Chow A, Zamarin D, DeWolf S, Shahid S, Bojilova V, Rusk N, Balachandran VP, McPherson A, Shah SP, Greenbaum BD. An information-theoretic framework for inferring T cell dynamics from single-cell RNA and T cell receptor sequencing. Nat Genet. 2026 Nov 5. [Epub ahead of print] PubMed PMID: 42988899
• Lupo KB, Panjwani MK, Halawi AG, Shahid S, Sottile R, Lawry C, Kolk G, Kontopoulos T, Daniyan AF, Chandran SS, Klebanoff CA, Hsu KC. Engineered NKG2C CD8 TKLR cells exhibit effective antitumor control in mice while mitigating cytokine release syndrome. J Clin Invest. 2026 Oct 20. [Epub ahead of print] PubMed PMID: 42905522
• Shahid, S, Mathew, SC, Souness, S, Burns, ER, Um, JS, Cihan, A, Yoo, S, Cai, W, Pohl, MA, Fujino, T, Zhang, P, Lewis, J, Siddiquee, A, Feinberg, TY, You, D, Dela Cruz, FS, Kung, AL, Lorenz, IC, de Stanchina, E, Devlin, S, Brentjens, RJ, Daniyan, AF. Developing an Optimal CD371-targeting IL-18 Secreting CAR T cell. Journal for ImmunoTherapy of Cancer. (Manuscript accepted on 10/23/2026; in press).
• Shahid, S, Prockop, SE, Flynn, GC, Mauguen, A, White, CO, Bieler, J, McAvoy D, Hosszu K, Cancio, MI, Jakubowski, AA, Scaradavou, A, Boelens, JJ, Sauter, CS, Perales, MA, Giralt, SA, Taylor, C, Chaudhari, J, Wang, X, Riviere, I, Sadelain, M, Brentjens, RJ, Kernan, NA, O’Reilly, RJ, Curran, KJ. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Advances. 2025;9(7): 1644–1657. https://doi.org/10.1182/bloodadvances.2024015157.
• Zhang P, Cao Z, Pan X, Liu Y, Castro C, Kim WJ, Fujino T, Lewis J, Rahman J, Shahid S, Um J, Burns E, Chen B, Cai W, Ortiz-Pacheco J, Li Z, Monetti M, Vakoc CR, Daniyan AF, Abdel-Wahab O, Shi J. Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies. Cancer Discov. 2025 Dec 2;15(12):2530-2553. PubMed PMID: 40788260
• Shahid S, Prockop SE, Flynn GC, Mauguen A, White CO, Bieler J, McAvoy D, Hosszu K, Cancio MI, Jakubowski AA, Scaradavou A, Boelens JJ, Sauter CS, Perales MA, Giralt SA, Taylor C, Chaudhari J, Wang X, Rivière I, Sadelain M, Brentjens RJ, Kernan NA, O'Reilly RJ, Curran KJ. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Adv. 2025 Apr 8;9(7):1644-1657. PubMed PMID: 39908482
• Shahid S, Curran KJ. Predicting CAR T-cell toxicity: insurance for CAR crashes. Blood Adv. 2025 Jan 28;9(2):335-336. PubMed PMID: 39820470
• Zhang P, Cao Z, Pan X, Liu Y, Castro C, Kim WJ, Fujino T, Lewis J, Rahman J, Shahid S, Um J, Burns E, Chen B, Cai W, Ortiz-Pacheco J, Li Z, Monetti M, Vakoc CR, Daniyan AF, Abdel-Wahab O, Shi J. Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. Cancer Discov. 2025 Aug 12. [Epub ahead of print] PubMed PMID: 40788260
• Shahid S, Prockop SE, Flynn GC, Mauguen A, White CO, Bieler J, McAvoy D, Hosszu K, Cancio MI, Jakubowski AA, Scaradavou A, Boelens JJ, Sauter CS, Perales MA, Giralt SA, Taylor C, Chaudhari J, Wang X, Rivière I, Sadelain M, Brentjens RJ, Kernan NA, O'Reilly RJ, Curran KJ. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Adv. 2025 Apr 8;9(7):1644-1657. PubMed PMID: 39908482
• Shahid S, Curran KJ. Predicting CAR T-cell toxicity: insurance for CAR crashes. Blood Adv. 2025 Jan 28;9(2):335-336. PubMed PMID: 39820470
• Lupo KB, Panjwani MK, Shahid S, Sottile R, Lawry C, Kolk G, Kontopolous T, Daniyan AF, Chandran SS, Klebanoff CA, Hsu KC. Engineered NKG2C ( ) NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome. bioRxiv. 2024 Aug 1. PubMed PMID: 39211122

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation

• Children's Hospital Colorado

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Pediatrics, Board Certification (2019)
• Pediatric Hematology / Oncology, Board Certification (2023)